The Food and Drug Administration is advising consumers not to purchase or use Rhino Gummy Royal 50000, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.
Similar Posts
Drug Safety and Risk Management Advisory Committee Roster
This page contains the DSARM roster, which lists the current members and the current number of vacancies for the committee.Patient-Focused Drug Development
The OCE PFDD program fosters collaboration between FDA centers and external stakeholders involved in patient outcomes research in cancer populations.Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial Due to Out-of-Specification Endotoxin Results in Certain Reserve Samples
FOR IMMEDIATE RELEASE – Nov. 6,2025 – LAKE ZURICH, Ill.— Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is voluntarily recalling three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection, USP, 20 mgFrequently Asked Questions about Drug Shortages
This page answers frequently asked questions (FAQ) about drug shortages such as what is a drug shortage, how many per year, how the FDA addresses and takes action on shortages, how the FDA notifies the public, what manufacturers are supposed to report to the FDA, and reasons for many drug shortagesGepotidacin – Oral Products
Gepotidacin – Oral ProductsSprout Health Partners LLC dba Sprout Health – 09/09/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet